Evidence map›Paper›PMID 18923022›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2008

Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration.

Koen Poesen, Diether Lambrechts, Philip Van Damme, Joke Dhondt, Florian Bender, Nicolas Frank, Elke Bogaert, Bart Claes, Line Heylen, An Verheyen and 11 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Endothelial Dysfunction in Obesity and Therapeutic Targets.Advances in experimental medicine and biology · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Multifaceted roles of pericytes in central nervous system homeostasis and disease.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Review
  17. Article
  18. Article
  19. Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 4 countries.

Koen PoesenVesalius Research Center, Katholieke Universiteit Leuven, Leuven B-3000, Belgium.
Diether Lambrechts
Philip Van Damme
Joke Dhondt
Florian Bender
Nicolas Frank
Elke Bogaert
Bart Claes
Line Heylen
An Verheyen
Katrien Raes
Marc Tjwa
Ulf Eriksson
Masabumi Shibuya
Rony Nuydens
Ludo Van Den Bosch
Theo Meert
Rudi D'Hooge
Michael Sendtner
Wim Robberecht
Peter Carmeliet
Vlaams Instituut voor Biotechnologie · BEUniversity of Würzburg · DEJanssen (Belgium) · BEKU Leuven · BELudwig Cancer Research · SETokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although vascular endothelial growth factor-B (VEGF-B) is a homolog of the angiogenic factor VEGF, it has only minimal angiogenic activity, raising the question of whether this factor has other (more relevant) biological properties. Intrigued by the possibility that VEGF family members affect neuronal cells, we explored whether VEGF-B might have a role in the nervous system. Here, we document that the 60 kDa VEGF-B isoform, VEGF-B(186), is a neuroprotective factor. VEGF-B(186) protected cultured primary motor neurons against degeneration. Mice lacking VEGF-B also developed a more severe form of motor neuron degeneration when intercrossed with mutant SOD1 mice. The in vitro and in vivo effects of VEGF-B(186) were dependent on the tyrosine kinase activities of its receptor, Flt1, in motor neurons. When delivered intracerebroventricularly, VEGF-B(186) prolonged the survival of mutant SOD1 rats. Compared with a similar dose of VEGF, VEGF-B(186) was safer and did not cause vessel growth or blood-brain barrier leakiness. The neuroprotective activity of VEGF-B, in combination with its negligible angiogenic/permeability activity, offers attractive opportunities for the treatment of neurodegenerative diseases.

Indexed as

Amyotrophic Lateral SclerosisAnimalsHumansLigandsMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMotor NeuronsNerve DegenerationProtein IsoformsRatsRats, Sprague-DawleyRats, WistarSuperoxide DismutaseSuperoxide Dismutase-1LigandsProtein IsoformsSOD1 protein, humanSod1 protein, mouseSod1 protein, ratSuperoxide DismutaseSuperoxide Dismutase-1Vascular Endothelial Growth Factor BVascular Endothelial Growth Factor Receptor-1

Identifiers

PMID18923022
PMCPMC6671326
OpenAlexW1973610175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.